Ponatinib efficacy and safety in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure: Results from a phase 2 study.

被引：0
|
作者：
Heinrich, Michael C.
von Mehren, Margaret
Demetri, George D.
Fletcher, Jonathan A.
Sun, Jichao G.
Kerstein, David
Conlan, Maureen G.
George, Suzanne
机构：
[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA
[3] Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA
[4] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA
[5] Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA
[6] Ariad Pharmaceut Inc, Cambridge, MA USA
[7] ARIAD Pharmaceut Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10535
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I study of the safety and pharmacokinetics of epitinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced solid tumors
    Zhou, Qing
    Wu, Yi Long
    Yu, Xiyong
    Yang, Jinji
    Wen, Limin
    Sai, Yang
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] A Phase I Study of dasatinib, a SRC and multi-kinase inhibitor, in patients (pts) with GIST and other solid tumors
    Morgan, J.
    Demetri, G.
    Wang, D.
    MacPherson, I.
    LoRusso, P.
    van den Abbeele, A.
    Brunton, V.
    Luo, R.
    Voi, M.
    Evans, T.
    EJC SUPPLEMENTS, 2006, 4 (12): : 118 - 118
  • [33] Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
    Kollmannsberger, Christian K.
    Sharma, Sunil
    Shapiro, Geoffrey
    Chi, Kim N.
    Christensen, James
    Tassell, Vanessa Roberts
    Chao, Richard C.
    Faltaos, Demiana
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
    Serrano, Cesar
    Leal, Alessandro
    Phallen, Jillian
    Marino-Enriquez, Adrian
    Kuang, Yanan
    Triplett, Olivia
    Morgan, Jeffrey A.
    Barysauskas, Constance
    Wagner, Andrew J.
    Demetri, George D.
    Velculescu, Victor E.
    Paweletz, Cloud
    Fletcher, Jonathan A.
    George, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] Safety of ipilimumab in patients (pts) with untreated, advanced melanoma alive beyond 2 years: Results from a phase III study.
    Thomas, Luc
    Wolchok, Jedd D.
    Garbe, Claus
    Lebbe, Celeste
    Bondarenko, Igor
    Rodrigues, Kristen
    Konto, Cyril
    Chin, Kevin M.
    Francis, Stephen
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib vs placebo in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes
    Reichardt, P.
    Demetri, G.
    Kang, Y-K
    Blay, J-Y
    Joensuu, H.
    Maki, R. G.
    Rutkowski, P.
    Hohenberger, P.
    Gelderblom, H.
    Leahy, M. G.
    von Mehren, M.
    Schoffski, P.
    Blackstein, M. E.
    Le Cesne, A.
    Badalamenti, G.
    Xu, J.
    Nishida, T.
    Kuss, I
    Casali, P. G.
    ONKOLOGIE, 2013, 36 : 179 - 180
  • [37] A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors
    Sarker, Debashis
    Molife, Rhoda
    Evans, T. R. Jeffrey
    Hardie, Maryon
    Marriott, Cheryl
    Butzberger-Zimmerli, Priska
    Morrison, Rosemary
    Fox, Judith A.
    Heise, Carla
    Louie, Sharianne
    Aziz, Natasha
    Garzon, Felix
    Michelson, Glenn
    Judson, Ian R.
    Jadayel, Dalal
    Braendle, Edgar
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2008, 14 (07) : 2075 - 2081
  • [38] Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.
    Sikic, B. I.
    Eckhardt, S. G.
    Gallant, G.
    Burris, H. A.
    Camidge, D. R.
    Colevas, A. D.
    Jones, S. F.
    Messersmith, W. A.
    Wakelee, H. A.
    Li, H.
    Kaminker, P. G.
    Morris, S.
    Infante, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST).
    Qiu, Haibo
    Zhou, Zhiwei
    Zhou, Ye
    Wan, XiangBin
    Tao, Kaixiong
    Li, Yong
    Wu, Xin
    Liu, Lihui
    Chen, Zi
    Men, Lichuang
    Liang, Zhiyan
    Lu, Ming
    Jiang, Lixin
    Yang, Dajun
    Xu, Rui-Hua
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] A phase 2 study of the Aurora A kinase (AAK) tyrosine kinase inhibitor (TKI) alisertib (MLN8237) in patients (pts) with pretreated urothelial cancer (UC)
    Necchi, Andrea
    Raggi, Daniele
    Lo Vullo, Salvatore
    Mariani, Luigi
    Giannatempo, Patrizia
    Calareso, Giuseppina
    Togliardi, Elena
    Nicolai, Nicola
    Perrone, Federica
    Pelosi, Giuseppe
    Salvioni, Roberto
    De Braud, Filippo G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
12345